- Home
- WGSWW vs SCLXW Comparison
WGSWW vs SCLXW Comparison
Compare WGSWW & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WGSWW
- SCLXW
- Stock Information
- Founded
- WGSWW 2017
- SCLXW N/A
- Country
- WGSWW United States
- SCLXW United States
- Employees
- WGSWW 1000
- SCLXW 115
- Industry
- WGSWW Retail: Computer Software & Peripheral Equipment
- SCLXW Biotechnology: Pharmaceutical Preparations
- Sector
- WGSWW Technology
- SCLXW Health Care
- Exchange
- WGSWW Nasdaq
- SCLXW Nasdaq
- Market Cap
- WGSWW N/A
- SCLXW N/A
- IPO Year
- WGSWW N/A
- SCLXW N/A
- Fundamental
- Price
- WGSWW $0.03
- SCLXW $0.11
- Analyst Decision
- WGSWW
- SCLXW
- Analyst Count
- WGSWW 0
- SCLXW 0
- Target Price
- WGSWW N/A
- SCLXW N/A
- AVG Volume (30 Days)
- WGSWW 36.6K
- SCLXW 4.0K
- Earning Date
- WGSWW 02-18-2025
- SCLXW 03-07-2025
- Dividend Yield
- WGSWW N/A
- SCLXW N/A
- EPS Growth
- WGSWW N/A
- SCLXW N/A
- EPS
- WGSWW N/A
- SCLXW N/A
- Revenue
- WGSWW $305,450,000.00
- SCLXW $55,152,000.00
- Revenue This Year
- WGSWW N/A
- SCLXW N/A
- Revenue Next Year
- WGSWW N/A
- SCLXW N/A
- P/E Ratio
- WGSWW N/A
- SCLXW N/A
- Revenue Growth
- WGSWW 50.79
- SCLXW 22.02
- 52 Week Low
- WGSWW $0.17
- SCLXW $0.18
- 52 Week High
- WGSWW $0.21
- SCLXW $0.18
- Technical
- Relative Strength Index (RSI)
- WGSWW N/A
- SCLXW N/A
- Support Level
- WGSWW N/A
- SCLXW N/A
- Resistance Level
- WGSWW N/A
- SCLXW N/A
- Average True Range (ATR)
- WGSWW 0.00
- SCLXW 0.00
- MACD
- WGSWW 0.00
- SCLXW 0.00
- Stochastic Oscillator
- WGSWW 0.00
- SCLXW 0.00
About WGSWW GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.
About SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.